Insertion/Deletion Polymorphisms in the ΔNp63 Promoter Are a Risk Factor for Bladder Exstrophy Epispadias Complex

PLoS Genetics

Volumn 8, Issue 12, 2012, Pages

  Wilkins, Simon ^a   Zhang, Ke Wei ^a   Mahfuz, Istiak ^a   Quantin, Renaud ^a   D'Cruz, Nancy ^a   Hutson, John ^b   Ee, Michael ^c   Bagli, Darius ^d   Aitken, Karen ^d   Fong, Fion Nga Yin ^e   Ng, Patrick Kwok Shing ^e   Tsui, Stephen Kwok Wing ^e   Fung, Wendy Yin Wan ^e   Banu, Tahmina ^f   Thakre, Atul ^g   Johar, Kaid ^g   Jaureguizar, Enrique ^h   Li, Long ⁱ   Cheng, Wei ^a,j  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL HOBART HOSPITAL   (Australia)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f CHITTAGONG MEDICAL COLLEGE HOSPITAL   (Bangladesh)

^g CIVIL HOSPITAL   (India)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ CAPITAL INSTITUTE OF PEDIATRICS   (China)

^j MONASH CHILDREN S HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; PROTEIN P63;

ARTICLE; BLADDER EPITHELIUM; BLADDER EXSTROPHY; CELL PROLIFERATION; CONTROLLED STUDY; DNA SEQUENCE; EMBRYO; ENZYME ASSAY; EPISPADIAS; ETHNICITY; EXON; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INDEL MUTATION; MAJOR CLINICAL STUDY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NP63 GENE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPIC VARIATION; PROMOTER REGION; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; RNA EXTRACTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TP63 GENE;

MAMMALIA; MUS;

EID: 84872024958     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1003070     Document Type: Article

References (33)

1. Martinez-Frias ML, Bermejo E, Rodriguez-Pinilla E, Frias JL, (2001) Exstrophy of the cloaca and exstrophy of the bladder: two different expressions of a primary developmental field defect. Am J Med Genet 99: 261-269.
2. Gearhart JP, Jeffs RD, (1989) State-of-the-art reconstructive surgery for bladder exstrophy at the Johns Hopkins Hospital. Am J Dis Child 143: 1475-1478.
3. Boyadjiev SA, Dodson JL, Radford CL, Ashrafi GH, Beaty TH, et al. (2004) Clinical and molecular characterization of the bladder exstrophy-epispadias complex: analysis of 232 families. BJU Int 94: 1337-1343.
4. Nelson CP, Dunn RL, Wei JT, (2005) Contemporary epidemiology of bladder exstrophy in the United States. J Urol 173: 1728-1731.
5. Froster UG, Heinritz W, Bennek J, Horn LC, Faber R, (2004) Another case of autosomal dominant exstrophy of the bladder. Prenat Diagn 24: 375-377.
6. Ludwig M, Ruschendorf F, Saar K, Hubner N, Siekmann L, et al. (2009) Genome-wide linkage scan for bladder exstrophy-epispadias complex. Birth Defects Res A Clin Mol Teratol 85: 174-178.
7. Shapiro E, Lepor H, Jeffs RD, (1984) The inheritance of the exstrophy-epispadias complex. J Urol 132: 308-310.
8. Reutter H, Qi L, Gearhart JP, Boemers T, Ebert AK, et al. (2007) Concordance analyses of twins with bladder exstrophy-epispadias complex suggest genetic etiology. Am J Med Genet A 143A: 2751-2756.
9. Cheng W, Jacobs WB, Zhang JJ, Moro A, Park JH, et al. (2006) DeltaNp63 plays an anti-apoptotic role in ventral bladder development. Development 133: 4783-4792.
10. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR, (2004) p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 18: 126-131.
11. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, et al. (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2: 305-316.
12. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, et al. (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713.
13. Baskin LS, Hayward SW, Young P, Cunha GR, (1996) Role of mesenchymal-epithelial interactions in normal bladder development. J Urol 156: 1820-1827.
14. Ching BJ, Wittler L, Proske J, Yagnik G, Qi L, et al. (2010) p63 (TP73L) a key player in embryonic urogenital development with significant dysregulation in human bladder exstrophy tissue. Int J Mol Med 26: 861-867.
15. Rodriguez S, Gaunt TR, Day IN, (2009) Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169: 505-514.
16. Gaunt TR, Rodriguez S, Day IN, (2007) Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics 8: 428.
17. Ni C, Ye Y, Wang M, Qian H, Song Z, et al. (2009) A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with risk of coal workers' pneumoconiosis. J Toxicol Environ Health A 72: 712-716.
18. Miceli-Richard C, Gestermann N, Ittah M, Comets E, Loiseau P, et al. (2009) The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjogren's syndrome. Arthritis Rheum 60: 1991-1997.
19. Burchard EG, Silverman EK, Rosenwasser LJ, Borish L, Yandava C, et al. (1999) Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma. Am J Respir Crit Care Med 160: 919-922.
20. Kulozik AE, Bellan-Koch A, Bail S, Kohne E, Kleihauer E, (1991) Thalassemia intermedia: moderate reduction of beta globin gene transcriptional activity by a novel mutation of the proximal CACCC promoter element. Blood 77: 2054-2058.
21. Sun T, Gao Y, Tan W, Ma S, Shi Y, et al. (2007) A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 39: 605-613.
22. Frank B, Rigas SH, Bermejo JL, Wiestler M, Wagner K, et al. (2008) The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat 111: 139-144.
23. Haiman CA, Garcia RR, Kolonel LN, Henderson BE, Wu AH, et al. (2008) A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet 40: 259-260; author reply 260-251.
24. Pittman AM, Broderick P, Sullivan K, Fielding S, Webb E, et al. (2008) CASP8 variants D302H and -652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. Br J Cancer 98: 1434-1436.
25. Ihrie RA, Marques MR, Nguyen BT, Horner JS, Papazoglu C, et al. (2005) Perp is a p63-regulated gene essential for epithelial integrity. Cell 120: 843-856.
26. Qi L, Chen K, Hur DJ, Yagnik G, Lakshmanan Y, et al. (2011) Genome-wide expression profiling of urinary bladder implicates desmosomal and cytoskeletal dysregulation in the bladder exstrophy-epispadias complex. Int J Mol Med 27: 755-765.
27. Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, et al. (1999) Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 99: 143-153.
28. Maas SM, de Jong TP, Buss P, Hennekam RC, (1996) EEC syndrome and genitourinary anomalies: an update. Am J Med Genet 63: 472-478.
29. Chuangsuwanich T, Sunsaneevithayakul P, Muangsomboon K, Limwongse C, (2005) Ectrodactyly-ectodermal dysplasia-clefting (EEC) syndrome presenting with a large nephrogenic cyst, severe oligohydramnios and hydrops fetalis: a case report and review of the literature. Prenat Diagn 25: 210-215.
30. Chilosi M, Zamo A, Brighenti A, Malpeli G, Montagna L, et al. (2003) Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. Virchows Arch 443: 175-183.
31. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
32. Ince TA, Cviko AP, Quade BJ, Yang A, McKeon FD, et al. (2002) p63 Coordinates anogenital modeling and epithelial cell differentiation in the developing female urogenital tract. Am J Pathol 161: 1111-1117.
33. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, et al. (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-718.